Abstract
Background: Systemic pulmonary delivery is considered to have advantages over oral or intravenous administration for certain drugs.
Methods: In this article, we review the effects of intrinsic drug properties and drug loading carriers on the pharmacokinetic parameters of inhaled drugs in the context of use in systemic pulmonary delivery.
Results: The delivery of drugs via inhalation can be advisable to achieve a fast onset of action; enhance the systemic bioavailability of drugs with poor oral absorption, including peptides and proteins; avoid invasive administration and improve patient compliance. To optimize the functioning of this delivery system, there is high demand for a systematic understanding of the pharmacokinetic characteristics, which are closely related to the pharmacodynamic and toxicological effects.
Conclusion: The pharmacokinetic parameters of inhaled drug products are affected by many factors, including physiological and pathological variables and the intrinsic drug and formulation properties.
Keywords: Pharmacokinetic, inhaled, systemic delivery, inhaled carriers, drug’s intrinsic property, bioavailability.
Current Pharmaceutical Design
Title:Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Volume: 22 Issue: 17
Author(s): Xiao Hu, Fei-Fei Yang and Yong-Hong Liao
Affiliation:
Keywords: Pharmacokinetic, inhaled, systemic delivery, inhaled carriers, drug’s intrinsic property, bioavailability.
Abstract: Background: Systemic pulmonary delivery is considered to have advantages over oral or intravenous administration for certain drugs.
Methods: In this article, we review the effects of intrinsic drug properties and drug loading carriers on the pharmacokinetic parameters of inhaled drugs in the context of use in systemic pulmonary delivery.
Results: The delivery of drugs via inhalation can be advisable to achieve a fast onset of action; enhance the systemic bioavailability of drugs with poor oral absorption, including peptides and proteins; avoid invasive administration and improve patient compliance. To optimize the functioning of this delivery system, there is high demand for a systematic understanding of the pharmacokinetic characteristics, which are closely related to the pharmacodynamic and toxicological effects.
Conclusion: The pharmacokinetic parameters of inhaled drug products are affected by many factors, including physiological and pathological variables and the intrinsic drug and formulation properties.
Export Options
About this article
Cite this article as:
Hu Xiao, Yang Fei-Fei and Liao Yong-Hong, Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128150005
DOI https://dx.doi.org/10.2174/1381612822666160128150005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Risk and Benefit of Statins in Stroke Secondary Prevention
Current Vascular Pharmacology Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot topic: Childhood Asthma - The State of Play in 2010 (Guest Editor: Steve Turner)]
Current Pediatric Reviews Exercise Rehabilitation for the Patient with Intermittent Claudication: A highly Effective yet Underutilized Treatment
Current Drug Targets - Cardiovascular & Hematological Disorders Disulfide Bridges in Defensins
Current Topics in Medicinal Chemistry Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application
Current Vascular Pharmacology Current Understanding of the Mechanism and Role of ROS in Angiotensin II Signal Transduction
Current Pharmaceutical Biotechnology The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats
Current Drug Therapy Pulmonary Hypertension: Types and Treatments
Current Cardiology Reviews Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Disruption of Circadian Rhythms and Sleep on Critical Illness and the Impact on Cardiovascular Events
Current Pharmaceutical Design Basal Septal Hypertrophy
Current Cardiology Reviews Is there a Relationship between Endothelial Dysfunction of the Brachial Artery, Carotid Intima-Media Thickness and Soluble Receptors of Tumor Necrosis Factor-Alpha?
Vascular Disease Prevention (Discontinued) Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies
Current Drug Targets Efficacy and Safety of Bevacizumab in Glioblastomas
Current Medicinal Chemistry Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Thienopyridines in Percutaneous Coronary Interventions: Standard Procedures and High Risk Subsets
Current Pharmaceutical Design The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Current Pharmaceutical Design